# OPM-101

Source: https://onco.cc/drugs/opm-101/  
OnCo record `opm-101` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

OPM-101 is an experimental oral small-molecule kinase inhibitor from Oncodesign Precision Medicine, in phase 1 trials for advanced melanoma resistant to anti-PD-1.

## Summary

OPM-101 is an oral small-molecule kinase inhibitor (macrocyclic, Nanocyclix platform) from Oncodesign Precision Medicine. A highly selective oral RIPK2 inhibitor that blocks the NOD2/RIPK2 pathway; the company says it is designed to reprogram immune responses in cancer and overcome resistance to immunotherapy. Its furthest stage is phase 1, for advanced melanoma resistant to anti-PD-1. ClinicalTrials.gov registers it in one study linked below. Phase 1 in healthy volunteers completed (SAD and MAD). REVERT phase 1b/2a with pembrolizumab in anti-PD-1-resistant melanoma registered, not yet recruiting (NCT07040436). Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: OPM-101
- Modality: Oral small-molecule kinase inhibitor (macrocyclic, Nanocyclix platform)
- Mechanism: A highly selective oral RIPK2 inhibitor that blocks the NOD2/RIPK2 pathway; the company says it is designed to reprogram immune responses in cancer and overcome resistance to immunotherapy.

## Sources

- Oncodesign Precision Medicine: oncodesign.com: https://www.oncodesign.com/our-pipeline/opm-101/
- Oncodesign Precision Medicine: oncodesign.com: https://www.oncodesign.com/our-pipeline/opm-101/
- Oncodesign Precision Medicine: clinicaltrials.gov: https://clinicaltrials.gov/study/NCT07040436
- ClinicalTrials.gov: trials of OPM-101: https://clinicaltrials.gov/search?intr=OPM-101

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- targets: [RIPK2](https://onco.cc/targets/ripk2/)
- companies: [Oncodesign Precision Medicine](https://onco.cc/companies/oncodesign-precision-medicine/)
- trials: [Assessment of Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1](https://onco.cc/trials/nct07040436/)

---
JSON: https://onco.cc/api/v1/entities/opm-101.json